Company Flex Pharma Inc Nasdaq
Equities
US33938A1051
Biotechnology & Medical Research
Business Summary
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Arthur
CEO | Chief Executive Officer | 61 | 19/19/19 |
Mark Rosenblum
DFI | Director of Finance/CFO | 70 | 10/19/10 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19/19/19 |
Nadeem Q. Mirza
PRN | Corporate Officer/Principal | - | 23/20/23 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Arnold Hanish
BRD | Director/Board Member | 76 | 19/19/19 |
Paul Lammers
BRD | Director/Board Member | 66 | 19/19/19 |
Jonathan Lieber
BRD | Director/Board Member | 54 | 19/20/19 |
William McVicar
CHM | Chairman | 66 | 19/19/19 |
Bruce McCreedy
BRD | Director/Board Member | 64 | 19/19/19 |
Tess Burleson
BRD | Director/Board Member | 57 | 19/19/19 |
David Arthur
CEO | Chief Executive Officer | 61 | 19/19/19 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 597,054 | 560,776 ( 93.92 %) | 0 | 93.92 % |
Company contact information
Salarius Pharmaceuticals, Inc.
2450 Holcombe Boulevard Suite X
77021, Houston
+
http://salariuspharma.comSector
1st Jan change | Capi. | |
---|---|---|
+25.83% | 4.66TCr | |
+45.38% | 4.17TCr | |
+0.69% | 4.12TCr | |
+30.52% | 3.24TCr | |
+22.30% | 2.82TCr | |
-6.35% | 2.81TCr | |
+49.25% | 1.45TCr | |
+49.18% | 1.37TCr | |
+3.45% | 1.22TCr |